The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1261
May 20, 2007
View Complete Issue         Table of Contents 2019 
Insulin-like Growth Factor-1 for Severe Growth Failure
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Insulin-like Growth Factor-1 for Severe Growth Failure
May 20, 2007 (Issue: 1261)
Mecasermin (Increlex - Tercica), which is injected subcutaneously, has been approved by the FDA for treatment of growth failure in children with severe primary insulin-like growth factor (IGF-1) deficiency. Mecasermin is recombinant human (rh) IGF-1....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Insulin-like Growth Factor-1 for Severe Growth Failure
Article code: 1261b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.